Presbia PLC

What Presbia PLC does

Presbia PLC is an Ireland-domiciled, publicly traded ophthalmic medical device company (OTC: LENSF) founded in 2008 and headquartered in Dublin, with operational presence in China clinical sites and event-driven commercial activity in Europe and the Middle East. The company develops and commercializes a single flagship product, the Presbia Flexivue Microlens, a hydrophilic, biocompatible intracorneal inlay implanted in the non-dominant eye via femtosecond laser to correct presbyopia. The device uses a bifocal optical design — a 1.6 mm central plano zone for distance vision surrounded by a peripheral refractive add zone for near vision — and is reversible, exchangeable, and ultra-thin (~15 micrometers edge thickness), distinguishing it from ablative laser procedures.

The company generates revenue through direct hardware sales of the microlens to ophthalmic surgeons, eye hospitals, and clinical trial sites across 43+ countries since receiving EU market approval in 2009. Go-to-market is B2B and professional-facing: field sales engagement, surgeon training at major ophthalmic congresses (ESCRS, ISOP, Middle East Ophthalmology Meeting), and clinical education through a professional portal and the Flexivue Calculator diopter-selection tool. Pricing is not publicly disclosed. Customer segmentation is horizontal across presbyopic adults (a ~1.8 billion global patient pool, with ~390 million in China alone), accessed exclusively through trained implanting surgeons.

The business is at an early commercial stage, with a small employee base (11–50), no disclosed revenue, and recent strategic emphasis on geographic expansion into China via a six-site multi-center clinical trial and into the Gulf Region via a distribution partnership with Al Rabiah Medical Center. Competitive positioning rests on regulatory incumbency (only EU-certified intracorneal microlens), a decade-plus clinical evidence base including a 421-patient US IDE trial, and patents held by Chief Scientist and founder Dr. Vladimir Feingold.

Name

Presbia PLC

Legal name

Presbia PLC

Website

https://presbia.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Presbia PLC is an Ireland-domiciled ophthalmic medical device company that develops and sells the Flexivue Microlens, a reversible intracorneal inlay implanted via femtosecond laser to correct presbyopia. It sells directly to ophthalmic surgeons and hospitals across 43+ countries, with active clinical and commercial expansion into China and the Gulf Region.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG)

Keywords

• Ophthalmic medical devices
• Presbyopia correction
• Corneal inlay implants
• Refractive surgery devices
• Intracorneal microlens

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. Flexivue Microlens Device Sales: Presbia generates revenue from the sale of its Flexivue Microlens implantable device to eye care professionals and hospitals. The procedure involves a one-time device implantation. The company operates globally across 43+ countries and regions since EU approval in 2009. Revenue is derived from direct device sales to clinical trial sites and commercial implanting centers.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Presbia PLC designs, develops, and commercializes the Presbia Flexivue Microlens, a hydrophilic biocompatible corneal inlay implanted via femtosecond laser into the corneal stroma of the non-dominant eye to correct presbyopia. The device provides simultaneous near and distance vision through pupil constriction and cortical blur suppression mechanisms and is sold to eye care professionals and hospitals across 43+ countries.

Product overview

Presbia PLC offers a single core product portfolio centered on the Presbia Flexivue Microlens®, the only EU-certified corneal intracorneal microlens for presbyopia correction. The company also provides a supporting Flexivue Calculator tool for eye care professionals to determine appropriate diopter prescriptions. The Flexivue Microlens is a small (3.2mm total diameter, 1.6mm central plano zone), extremely thin (15 micrometers edge thickness) hydrophilic device that is implanted in the non-dominant eye via femtosecond laser, using the eye's natural pupil response and neural blur suppression to enable seamless focus transition between near and distance vision. The procedure is reversible and replaceable.

Differentiator

Problem solved

Functional benefit

Brands

• Presbia Flexivue Microlens: A hydrophilic, biocompatible corneal microlens designed to address presbyopia by increasing depth of focus for near vision without compromising distance visual acuity. The only EU-certified corneal inlay microlens on the market.

Products and services

• Presbia Flexivue Microlens A hydrophilic, biocompatible corneal inlay (3.2mm total diameter, 1.6mm central plano zone, ~15 micrometer edge thickness) implanted within the corneal stroma of the non-dominant eye through a minimally invasive femtosecond laser procedure. It corrects presbyopia by increasing depth of focus for near vision while preserving distance visual acuity. The device is removable and replaceable and is sold to ophthalmic surgeons and hospitals.
• Flexivue Calculator An online clinical tool for eye care professionals that calculates the appropriate diopter power for Flexivue Microlens implantation based on patient sphere, cylinder, add, and age parameters.

Quantifiable outcome

• 76.2% of patients achieved complete spectacle independence for near tasks post-operatively, compared to 100% pre-operative dependence on glasses
• +6 more outcomes

Named customers6 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and secondary.

• Beijing Aier Yingzhi Eye HospitalcoreStrategic or Co-development Partner · 27 April 2026Participating clinical trial center in the multi-center OPC study. Hosted the official kickoff meeting in April 2026. Prof. Zhang Fengju serves as Principal Investigator and successfully completed inaugural surgical procedures. Trial is progressing with active patient recruitment.
• Eye Hospital of Wenzhou Medical UniversitycoreStrategic or Co-development Partner · 20 April 2026Co-leading a landmark multi-center clinical trial for the Flexivue Microlens in China. The Eye Hospital of Wenzhou Medical University's Refractive Surgery Center, with more than 30 years of clinical research expertise, is a principal investigator site. Prof. Chen Shihao and Prof. Qu Jia are key representatives. The institution is committed to GCP-compliant trial execution.
• Eye & ENT Hospital of Fudan UniversitycoreStrategic or Co-development Partner · 20 April 2026Co-leading the multi-center clinical trial alongside Wenzhou Medical University. Prof. Xingtao Zhou performed first Flexivue implantations at this institution. Serving as a principal investigator site in the OPC clinical trial evaluating efficacy and safety for near vision improvement in presbyopic patients.
• Tianjin Eye HospitalsecondaryStrategic or Co-development Partner · 20 April 2026Participating institution in the multi-center OPC clinical trial evaluating Flexivue Microlens efficacy and safety in Chinese presbyopic patients.
• Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong KongsecondaryStrategic or Co-development Partner · 20 April 2026Participating institution in the multi-center OPC clinical trial evaluating Flexivue Microlens efficacy and safety in Chinese presbyopic patients.
• Xiamen Eye Center of Xiamen UniversitysecondaryStrategic or Co-development Partner · 20 April 2026Participating institution in the multi-center OPC clinical trial evaluating Flexivue Microlens efficacy and safety in Chinese presbyopic patients.
• Dr. Sami Al Rabiah / Al Rabiah Medical Center (Gulf Region)coreChannel Partner/ Reseller/ Distributor · 10 October 2025Strategic partnership announced to expand Flexivue Microlens distribution across the Gulf Region. Dr. Sami M.H. Al-Rabiah has performed the surgical procedure and produced educational content for the technology. The partnership aims to bring the minimally invasive presbyopia correction solution to patients across Middle Eastern markets.
• Bo'ao Lecheng Aier Eye HospitalcoreStrategic or Co-development Partner · 28 September 2025First hospital in China to perform presbyopia correction surgeries utilizing the Presbia Flexivue Microlens. The landmark procedures were conducted under China's pioneering 'Chartered Medical Care, Pioneer Experimentation' policy framework, enabling domestic patients to access the internationally approved technology ahead of broader national availability.
• Aier Eye Hospital GroupcoreStrategic or Co-development Partner · 20 September 2025One of the world's largest ophthalmic healthcare networks. Partnered with Presbia to introduce Flexivue Microlens to China under the Bo'ao 'Chartered Medical Care, Pioneer Experimentation' policy. Prof. Zhang Fengju serves as Director of Ophthalmology and VP of the Presbyopia Management MDT Group within Aier. The group is committed to deepening the strategic collaboration to explore new frontiers in ophthalmic technology.
• Presbia Ireland LimitedcoreOthersPresbia Ireland Limited is the sponsoring entity for the multi-center clinical trial in China. The Irish subsidiary manages regulatory and clinical trial operations for the Chinese market entry.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Orasis Pharmaceuticals: Developed CSF-1, an FDA-approved presbyopia-correcting eye drop (Qlosi), offering a low-cost, non-surgical alternative to corneal inlay procedures such as the Flexivue Microlens.
• Visus Therapeutics: Clinical-stage company developing presbyopia-correcting eye drop therapies (BRIMOCHOL, etc.) — competes as a non-invasive alternative to surgical presbyopia correction for the same patient demographic.
• Lenz Therapeutics: Late-stage clinical company developing pharmacologic presbyopia-correcting eye drops (e.g., aceclidine-based programs) — a non-surgical modality that directly competes for the same presbyopic patient wallet Presbia targets.

Broad incumbents

• Alcon: Global ophthalmic incumbent offering multifocal and EDOF IOLs (PanOptix, Vivity) that compete with Flexivue for presbyopia-correcting surgical volume, plus femtosecond cataract systems and refractive surgical equipment.
• Carl Zeiss Meditec: Supplies SMILE refractive laser platforms, VisuMax femtosecond systems, and premium IOLs; competes with Flexivue for refractive surgery patient share and provides the femtosecond laser infrastructure used to implant Presbia's microlens.
• Johnson & Johnson Vision: Markets the TECNIS multifocal and Symfony IOLs alongside the iFS and Catalys femtosecond laser platforms — directly addresses the same presbyopia and refractive surgery customer (ophthalmic surgeons) as Presbia.
• Bausch + Lomb: Operates in cataract and refractive surgery with enVista and other IOLs, plus the Victus femtosecond platform — overlapping surgeon customers and competing presbyopia-correcting surgical options.

Direct peers

• STAAR Surgical: Develops and markets the EVO ICL (Implantable Collamer Lens), a phakic IOL for refractive correction invented by Presbia's own Chief Scientist Dr. Vladimir Feingold. STAAR is the most direct comparator as an implantable vision-correction company sharing the same inventor pedigree.
• SCHWIND eye-tech-solutions: Manufactures excimer and femtosecond refractive laser platforms (AMARIS, FEMTO) — competes head-to-head with Presbia for refractive surgery patient share and provides surgical equipment infrastructure to the same surgeon base.
• Ziemer Ophthalmic Systems: Specializes in low-energy femtosecond lasers for corneal surgery (FEMTO LDV Z8) — both supplies the laser technology used in Presbia's Flexivue implantation procedure and competes as a corneal refractive surgical platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/presbia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Presbia PLC